DGAP-News: AURELIUS Equity Opportunities sells UK fine chemical manufacturer Wychem to Ascensus Specialties


 

DGAP-News: AURELIUS Equity Opportunities SE & Co. KGaA / Key word(s): Disposal
AURELIUS Equity Opportunities sells UK fine chemical manufacturer Wychem to Ascensus Specialties

13.12.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


AURELIUS Equity Opportunities sells UK fine chemical manufacturer Wychem to Ascensus Specialties

- Successful exit after becoming part of AURELIUS' portfolio and repositioning of the company since 2016

- Being part of AURELIUS' chemical activities in the UK, Wychem today is a well-established company with a highly qualified team and a specialized product portfolio

- Wychem will play a vital role In Ascensus' European expansion

- Further transactions expected in the coming weeks

Grünwald/London, December 13, 2021 - AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8) today announces the sale of Wychem Limited ("Wychem") to Ascensus Specialties LLC ("Ascensus"), a U.S. based provider of specialty chemicals. The transaction resulted in a money-over-money multiple of 10.6x for AURELIUS.

Founded more than 50 years ago and becoming part of the AURELIUS portfolio in 2016, Wychem has been part of the AURELIUS' chemical activities in the UK and became a leading independent manufacturer of fine chemicals for pharmaceuticals and specialty applications in the local market.

The company offers a comprehensive range of more than 1,000 aromatics which are highly valued by more than 50 global customers across different industries. A team of more than 25 experts and a "kilo lab to plant full scale" capability allow for short innovation cycles. Backed by a comprehensive repositioning including investments in site expansion and capacity improvements carried out by AURELIUS, Wychem is now in excellent shape generating a high margin and strong cash flow.

On the back of this strong position in the European market, Wychem will play a vital role in Ascensus' Expansion. With foundations strongly rooted in chemistry and process, Wychem has been able to differentiate itself within the European market as a leader in process optimization without the cost burden of FDA regulation.

"Since being part of AURELIUS' portfolio, we have supported Wychem in its positioning and expansion in its markets and saw a consistently positive development of the company. Latest growth initiatives put the company at the forefront of a new phase of growth in the industry," said Matthias Täubl, CEO of AURELIUS Equity Opportunities SE & Co. KGaA. "I am pleased to see Wychem become an integral part of Ascensus' strategic expansion into the European market. On the back of a very successful year for AURELIUS and with a solidly filled transaction pipeline, we are confident to execute further deals in the near future."

"Wychem is a nimble, highly customer-centric organization with deep relationships across its global customer base of CDMO, pharmaceutical, and other specialty customers. The company's consistent growth and reliable supply to customers throughout the COVID-19 pandemic reflects its excellent reputation for service and quality. Wychem is an exciting addition to Ascensus and aligns with our commitment to servicing the pharmaceutical space", said Mike Huff, Chief Executive Officer of Ascensus.

AURELIUS was advised on the transaction by Opus Corporate Finance LLP (Financial) and DWF LLP (Legal).

A telephone conference with the AURELIUS Management Team will be held at 2pm CET on Monday, December 13, 2021 in English for interested investors and journalists. Please send an email to [email protected] to register.


ABOUT AURELIUS
AURELIUS Group is a pan-European asset management group with offices in Munich, London, Stockholm, Madrid, Amsterdam, Milan and Luxembourg.
Key investment platforms are its AURELIUS European Opportunities IV fund as well as listed AURELIUS Equity Opportunities SE & Co. KGaA ("AEO"; ISIN: DE000A0JK2A8), which acquire corporate carve-outs and companies with development potential in the mid-market (fund) and lower mid-market sector (AEO). The investment strategy's core element is operational support of its portfolio companies with a team of almost 100 in-house operating taskforce experts. AURELIUS Group also operates in the areas of growth capital, real estate opportunities and debt. With its group charity AURELIUS Refugee Initiative e.V., AURELIUS provides comprehensive support for refugees on their way towards a better life.

To find out more, visit www.aurelius-group.com

CONTACT
AURELIUS Group
Investor Relations & Corporate Communications
Phone: +49 (89) 544799 - 0
Fax: +49 (89) 544799 - 55
E-mail: [email protected]

 


 


13.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: AURELIUS Equity Opportunities SE & Co. KGaA
Ludwig-Ganghofer-Straße 6
82031 Grünwald
Germany
Phone: +49 (0)89 544 799-0
Fax: +49 (0)89 544 799-55
E-mail: [email protected]
Internet: www.aureliusinvest.de
ISIN: DE000A0JK2A8
WKN: A0JK2A
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Hamburg, Munich (m:access), Stuttgart, Tradegate Exchange
EQS News ID: 1256829

 
End of News DGAP News Service

1256829  13.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1256829&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 2.998,35 2.902,94 3.612,00 1.932,90 2.560,80 2.995,00 0,00
EBITDA1,2 272,56 65,72 80,30 167,60 249,70 154,40 0,00
EBITDA-Marge3 9,09 2,26 2,22 8,67 9,75 5,16
EBIT1,4 202,00 11,69 -84,20 222,70 115,80 29,40 0,00
EBIT-Marge5 6,74 0,40 -2,33 11,52 4,52 0,98 0,00
Jahresüberschuss1 484,49 -39,52 18,27 121,60 151,80 78,70 0,00
Netto-Marge6 16,16 -1,36 0,51 6,29 5,93 2,63 0,00
Cashflow1,7 -132,16 -50,00 -76,10 227,50 42,90 -41,50 0,00
Ergebnis je Aktie8 5,98 -1,43 -3,43 3,62 4,86 2,99 1,65
Dividende8 5,00 3,00 0,00 1,00 1,50 0,05 4,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Aurelius Equity Opportunities
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0JK2A 14,800 Halten 403,60
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
7,40 7,87 0,95 7,40
KBV KCV KUV EV/EBITDA
0,67 - 0,13 3,18
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,05 0,25 1,69 20.09.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.05.2023 10.08.2023 10.11.2022 27.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,45% 7,28% 8,82% 2,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu AURELIUS Equity Opportunities SE & Co. KGaA  ISIN: DE000A0JK2A8 können Sie bei EQS abrufen


Beteiligungen , A0JK2A , AR4 , HAM:AR4